Spectrum of use and tolerability of 5‐HT₃receptor antagonists

Gyermek L, 1995, J Clin Pharmacol, 35, 845, 10.1002/j.1552-4604.1995.tb04129.x

Coppen A, 1967, Br J Psychiatry, 113, 1237, 10.1192/bjp.113.504.1237

10.1093/jnci/83.9.613

10.1016/S0091-3057(01)00745-6

Andrews PL, 1992, Eur J Cancer, 28, S2–S6

Wolf H, 2000, Scand J Rheumatol, 29, 37, 10.1080/030097400446625

Ballatori E, 2003, Health Qual Life Outcomes, 17, 46, 10.1186/1477-7525-1-46

Lindley CM, 1992, Quality of life consequences of chemotherapy-induced emesis. Qual Life Res, 1, 331

Pendergrass KB, 1998, Cancer Pract, 6, 276, 10.1046/j.1523-5394.1998.00022.x

Kris MG, 1994, Delayed emesis following anticancer chemotherapy. Support Care Center, 2, 297

Cubeddu LX, 1992, Sem Oncol, 19, 2

Zeitz KP, 2002, J Neurosci, 22, 1010, 10.1523/JNEUROSCI.22-03-01010.2002

Sorbe BG, 1998, Cancer, 83, 1022, 10.1002/(SICI)1097-0142(19980901)83:5<1022::AID-CNCR29>3.0.CO;2-8

Lee CR, 1993, Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs, 46, 925

Yakushiji M, 1995, Gan To Kagaku Ryoho, 22, 1073

Gridelli C, 2003, Anticancer Res, 23, 2773

Walton SM, 2000, Expert Opin Pharmacother, 1, 207, 10.1517/14656566.1.2.207

Tonini G, 2003, Prevention of radiotherapy-induced emesis. J Exp Clin Cancer Res, 22, 17

10.1111/j.1368-5031.2004.0135.x

Dando TM, 2004, Drugs, 64, 777, 10.2165/00003495-200464070-00013

Feyer PC, 1998, Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer, 6, 253, 10.1007/s005200050163

Franzen L, 1996, Ann Oncol, 7, 587, 10.1093/oxfordjournals.annonc.a010675

10.2165/00003495-199200433-00008

Lanciano R, 2001, Cancer Invest, 19, 763, 10.1081/CNV-100107736

10.1159/000227173

Benoit Y, 1995, Med Pediatr Oncol, 25, 457, 10.1002/mpo.2950250607

Yarker YE, 1994, An update of its therapeutic use in nausea and vomiting induced by anti-neoplastic therapy. Drugs, 48, 761

Culy CR, 2001, Plosker GL. Ondansetron: a review of its use as an antiemetic in children. Paediatr Drugs, 3, 441

Roila F, 1998, Optimal selection of antiemetics in children receiving cancer chemotherapy. Sup-port Care Cancer, 6, 215

Cohen MM, 1986, Can Anaesth Soc J, 33, 22, 10.1007/BF03010904

Apfel CC, 1999, A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology, 91, 693

Macario A, 1999, Anaesth Analg, 89, 652, 10.1213/00000539-199911000-00030

Tramer MR, 1997, Anesthesiology, 87, 1277, 10.1097/00000542-199712000-00004

Kranke P, 2001, The influence of a dominating centre on a quantitative systematic review of granisetron for preventing postoperative nausea and vomiting. Acta Anaesthesiol Scand, 45, 659

Kranke P, 2002, Anaesthesiol Intensivmed, 43, 413

Kranke P, 2002, Anaesthesist, 51, 805, 10.1007/s00101-002-0373-y

Kovac AL, 2003, Drug Saf, 26, 227, 10.2165/00002018-200326040-00003

Gan TJ, 2003, Anesth Analg, 97, 62, 10.1213/01.ANE.0000068580.00245.95

Holt R, 2000, Tropisetron plus dexamethasone is more effective than tropisetron alone for the prevention of postoperative nausea and vomiting in children undergoing tonsillectomy. Paediatr Anaesth, 10, 181

Dillier CM, 2000, Tropisetron for prevention of nausea and vomiting in children undergoing tonsillectomy and/or adenoidectomy. Anaesthesist, 49, 275

Callahan MJ, 2002, A review of approved and investigational compounds. J Clin Gastroenterol, 35, 58, 10.1097/00004836-200207001-00011

10.1016/S0140-6736(00)02033-X

Camilleri M, 2001, Arch Intern Med, 161, 1733, 10.1001/archinte.161.14.1733

Lembo T, 2001, Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol, 96, 2662

10.1046/j.1365-2036.1999.00678.x

Lievre M, 2002, Br Med J, 325, 555, 10.1136/bmj.325.7364.555

Wilde MI, 1996, A review of its pharmacology and preliminary clinical findings in novel applications. Drugs, 52, 773

Shaath NM, 2001, Drugs Today (Barc), 37, 437, 10.1358/dot.2001.37.7.844186

Flake ZA, 2004, Practical selection of antiemetics. Am Fam Physician, 69, 1169

Pitkanen MT, 1993, Br J Anaesth, 71, 681, 10.1093/bja/71.5.681

Wang JJ, 2002, Anesth Analg, 94, 749, 10.1097/00000539-200203000-00050

Levine ME, 2000, Aviat Space Environ Med, 71, 1111

Van Hee R, 2003, Obes Surg, 13, 932, 10.1381/096089203322618803

Spath M, 2003, Schmerz, 17, 437, 10.1007/s00482-003-0256-4

Farber L, 2000, Scand J Rheumatol, 29, 49, 10.1080/030097400446643

Stratz T, 2001, Drug Exp Clin Res, 27, 113

Stratz T, 2002, Muller W. Local treatment of tendino-pathies: a comparison between tropisetron and depot corticosteroids combined with local anesthetics. Scand J Rheumatol, 31, 366

Spath M, 2002, Rheum Dis Clin North Am, 28, 319, 10.1016/S0889-857X(01)00014-X

Stratz T, 2003, Schmerz, 17, 200, 10.1007/s00482-003-0219-9

Voog, 2000, Immediate effects of the serotonin antagonist granisetron on temporomandibular joint pain in patients with systemic inflammatory disorders. Life Sci, 68, 591

Chappell AS, 1994, Neuropharmacology, 33, 509, 10.1016/0028-3908(94)90082-5

Yoshioka M, 1995, Pharmacol Biochem Behav, 51, 515, 10.1016/0091-3057(95)00045-X

Rex A, 1998, Pharmacol Biochem Behav, 59, 677, 10.1016/S0091-3057(97)00461-9

Johnson BA, 2003, Drugs Today (Barc), 39, 665, 10.1358/dot.2003.39.9.799475

10.1016/S0091-3057(96)00516-3